First Administration To Man Of An Oncolytic Herpesvirus-1 Vector Containing A Transgene For Granulocyte Macrophage Colony Stimulating Factor (OncoVEXGM-CSF): A Study Of Its Safety, Biodistribution And Biological Activity

Sponsor ID

001-01

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 1

Product

talimogene laherparepvec (T-VEC)

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.